Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Immune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have become the frontier of cancer treatment and successfully prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC). But the efficacy varies among different patient population, and many p...
| Published in: | Frontiers in Immunology |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1127071/full |
| _version_ | 1852712084990590976 |
|---|---|
| author | Kexun Zhou Kexun Zhou Shuo Li Shuo Li Yi Zhao Ke Cheng Ke Cheng |
| author_facet | Kexun Zhou Kexun Zhou Shuo Li Shuo Li Yi Zhao Ke Cheng Ke Cheng |
| author_sort | Kexun Zhou |
| collection | DOAJ |
| container_title | Frontiers in Immunology |
| description | Immune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have become the frontier of cancer treatment and successfully prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC). But the efficacy varies among different patient population, and many patients succumb to disease progression after an initial response to ICIs. Current research highlights the heterogeneity of resistance mechanisms and the critical role of tumor microenvironment (TME) in ICIs resistance. In this review, we discussed the mechanisms of ICIs resistance in NSCLC, and proposed strategies to overcome resistance. |
| format | Article |
| id | doaj-art-e9249d89f04e44288b3a5bfe3075ea35 |
| institution | Directory of Open Access Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| spelling | doaj-art-e9249d89f04e44288b3a5bfe3075ea352025-08-19T21:15:59ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-02-011410.3389/fimmu.2023.11270711127071Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancerKexun Zhou0Kexun Zhou1Shuo Li2Shuo Li3Yi Zhao4Ke Cheng5Ke Cheng6Abdominal Oncology Ward, Division of Medical Oncology, Cancer Center, State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu, ChinaAbdominal Oncology Ward, Division of Radiation Oncology, Cancer Center, State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, ChinaLung Cancer Center, West China Hospital Sichuan University, Chengdu, ChinaThe First Clinical Medical College of Lanzhou University, Lanzhou University, Lanzhou, ChinaAbdominal Oncology Ward, Division of Medical Oncology, Cancer Center, State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu, ChinaAbdominal Oncology Ward, Division of Radiation Oncology, Cancer Center, State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu, ChinaImmune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have become the frontier of cancer treatment and successfully prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC). But the efficacy varies among different patient population, and many patients succumb to disease progression after an initial response to ICIs. Current research highlights the heterogeneity of resistance mechanisms and the critical role of tumor microenvironment (TME) in ICIs resistance. In this review, we discussed the mechanisms of ICIs resistance in NSCLC, and proposed strategies to overcome resistance.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1127071/fullimmunotherapyresistancemechanismtumor microenvironmentlung cancer |
| spellingShingle | Kexun Zhou Kexun Zhou Shuo Li Shuo Li Yi Zhao Ke Cheng Ke Cheng Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer immunotherapy resistance mechanism tumor microenvironment lung cancer |
| title | Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer |
| title_full | Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer |
| title_fullStr | Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer |
| title_full_unstemmed | Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer |
| title_short | Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer |
| title_sort | mechanisms of drug resistance to immune checkpoint inhibitors in non small cell lung cancer |
| topic | immunotherapy resistance mechanism tumor microenvironment lung cancer |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1127071/full |
| work_keys_str_mv | AT kexunzhou mechanismsofdrugresistancetoimmunecheckpointinhibitorsinnonsmallcelllungcancer AT kexunzhou mechanismsofdrugresistancetoimmunecheckpointinhibitorsinnonsmallcelllungcancer AT shuoli mechanismsofdrugresistancetoimmunecheckpointinhibitorsinnonsmallcelllungcancer AT shuoli mechanismsofdrugresistancetoimmunecheckpointinhibitorsinnonsmallcelllungcancer AT yizhao mechanismsofdrugresistancetoimmunecheckpointinhibitorsinnonsmallcelllungcancer AT kecheng mechanismsofdrugresistancetoimmunecheckpointinhibitorsinnonsmallcelllungcancer AT kecheng mechanismsofdrugresistancetoimmunecheckpointinhibitorsinnonsmallcelllungcancer |